GHK-Cu: How a Three-Residue Peptide Carries Copper, and What That Explains

GHK-Cu is a complex of copper(II) with glycyl-L-histidyl-L-lysine, a tripeptide of three amino acids found naturally in human plasma. The peptide binds copper with high affinity, and the dominant explanation for its activity is that it functions as a physiological copper carrier: it holds the ion in a form that can be taken up by cells and handed to copper-dependent enzymes, rather than circulating free where it would be toxic 14. Downstream of that, the most reproducible reported effect is stimulation of extracellular matrix synthesis — collagen in particular — in fibroblast culture 2. The evidence is strongest in skin and in vitro, weaker elsewhere, and unusually concentrated in the output of a single investigator.

The molecule and its copper affinity

GHK is short enough to describe completely: glycine, then histidine, then lysine. What makes it chemically distinctive is not its size but its geometry. The histidine imidazole nitrogen, the N-terminal amine and the intervening peptide nitrogen together present a coordination site well matched to copper(II), and the resulting complex is stable at physiological pH 4. The affinity is high enough that GHK can compete for copper with albumin, the main copper-carrying protein in plasma.

This is the whole mechanistic foundation. Copper is required by a set of enzymes that includes lysyl oxidase, which cross-links collagen and elastin, and superoxide dismutase, which handles a specific class of reactive oxygen species. Copper is also destructive when unbound, because it catalyses reactions that generate free radicals. Biology therefore never transports copper free — it is always chaperoned. GHK is proposed to be one such chaperone, and the tissue effects attributed to it follow from what its cargo is used for.

Where it was found, and the plasma decline

GHK was identified in human plasma in the early 1970s, isolated in the course of work asking why liver tissue from younger donors behaved differently in culture from older tissue. The frequently quoted figure is that plasma GHK is on the order of 200 ng/mL at age 20 and falls to roughly 80 ng/mL by age 60 1. That decline is the origin of the compound's framing as an age-related repair signal, and it is worth handling carefully: a correlation between a declining plasma concentration and declining tissue repair capacity does not establish that the decline causes the decline in function, nor that restoring the concentration restores the function. Both are plausible. Neither is demonstrated.

Effects on the extracellular matrix

The most durable finding is from fibroblast culture. GHK-Cu was reported to stimulate collagen synthesis in cultured fibroblasts at nanomolar concentrations, an effect attributed to the copper complex rather than to the peptide alone 2. Subsequent work extended the finding to other matrix components — glycosaminoglycans, decorin and elastin among them — and to modulation of the matrix metalloproteinases that degrade matrix, which would matter because remodelling requires controlled breakdown as well as synthesis 4.

The coherence here is worth noting. A copper carrier should influence lysyl oxidase activity, lysyl oxidase cross-links collagen and elastin, and the reported effects are on collagen and elastin. The mechanism and the observations fit, which is a stronger position than most compounds in this field occupy.

The gene expression claim

A more recent line of argument holds that GHK influences the expression of a very large number of human genes — figures in the low thousands are cited — based on transcriptomic screening data, with the pattern described as shifting expression toward a healthier profile 13. This is the most-quoted claim about the compound and it needs the most careful reading.

Large-scale expression screens measure how a cell's transcriptome responds to a perturbation. A count of significantly changed transcripts is a measure of how much the cell reacted, not a measure of therapeutic benefit, and many compounds produce changes on that scale. The interpretive step — that the direction of change constitutes a shift toward health — is an inference layered on top of the data rather than a readout from it. The screen is real and the analysis is legitimate; the summary claim that GHK "resets" gene expression carries considerably more than the underlying method can support.

What human evidence exists

GHK-Cu has more human data than most compounds discussed alongside it, and it is important to be exact about what kind. The human work is overwhelmingly topical, in cosmetic formulations, with endpoints such as skin density, wrinkle depth, firmness and photodamage appearance. Studies are typically small, of short duration, and frequently conducted or funded by parties with a commercial interest in the formulation.

Delivery is a genuine constraint on interpreting this work. Skin penetration of the copper tripeptide has been examined directly in vitro across skin layers, and penetration is limited and layer-dependent 5. A topical result therefore says something about a formulation reaching viable epidermis, and very little about what the molecule would do administered by any other route. There is no meaningful published human pharmacokinetic profile for systemic administration.

The concentration of authorship

One structural feature of this literature should be stated plainly, because it changes how much weight the body of work can carry. A large share of published GHK research — including the foundational characterisation, the tissue-remodelling reviews and the gene expression analyses — involves the same investigator, who has held commercial interests in copper-peptide products 134. The 1988 collagen work was a collaboration with an independent French matrix biology group, which is part of why it carries more weight than the reviews that cite it 2.

This is not an allegation of misconduct and it does not invalidate the findings. It is the same consideration that applies to the BPC-157 literature, and it applies for the same reason: a result confirmed by groups with no stake in the outcome is stronger evidence than the same result reported repeatedly by one group. Where independent replication exists, it should be weighted more heavily. Where it does not, the finding should be held provisionally.

What "high affinity" has to mean here

The copper-carrier hypothesis depends on a quantitative condition that is easy to state and easy to skip past. Plasma copper is not free. It is bound, principally to ceruloplasmin, with an exchangeable fraction associated with albumin and with the histidine-containing small-molecule pool. For GHK to function as a carrier it must be able to acquire copper from that competing environment and release it where required — which means its affinity has to be high enough to compete with albumin, and not so high that the copper never comes off 4.

This is a narrower window than a simple statement of "high affinity" conveys. A carrier that binds too weakly never loads; one that binds too tightly becomes a sink rather than a shuttle. The chemistry of the GHK site — an N-terminal amine, the intervening peptide nitrogen and the histidine imidazole, together presenting a square-planar coordination geometry that copper(II) particularly favours — places it in approximately the right range, and this correspondence is the strongest part of the mechanistic case 1.

It is also where the case stops being demonstrated. That a molecule has appropriate binding chemistry establishes that it could perform the role. Showing that it does perform it in human tissue in vivo — that copper actually moves from GHK to a specific enzyme, in a physiologically relevant quantity, at concentrations the body actually achieves — is a separate experiment, and it is not one the current literature has completed.

The histidine problem

A specific and underappreciated complication follows from the same chemistry. Free histidine is itself a copper ligand and is present in plasma at concentrations far exceeding those of GHK. So is albumin, whose N-terminal sequence begins with aspartate-alanine-histidine and presents a copper site of the same general type. GHK is therefore not operating in an empty field; it is one species among several competing for the same ion, and it is not the most abundant of them.

This does not defeat the hypothesis. Carrier systems commonly work through relatively small, kinetically favoured pools rather than through mass action, and the reported biological activity at nanomolar concentrations 2 is consistent with something other than bulk copper transport being responsible. But it does mean the simple account — GHK carries copper into cells, copper enzymes do the rest — is a summary of a considerably more contested picture, and the specific route by which administered GHK-Cu would alter a copper-dependent process in human tissue has not been mapped.

What the evidence does not establish

• No controlled human trial has tested systemic GHK-Cu for a clinical endpoint. The human evidence base is topical and cosmetic.
• The copper-carrier mechanism is well argued from chemistry but has not been directly demonstrated to be the operative mechanism in human tissue in vivo.
• Copper load is a real consideration. The complex delivers copper, and copper has a narrow window between sufficiency and toxicity; no dosing safety envelope has been established in humans for non-topical routes.
• The gene expression findings are in vitro screening data, and the health-directional interpretation of them is an inference, not a measurement.
• The plasma decline with age is a correlation. Causation, and the reversibility of any consequence, are both unestablished.

How to read this literature

GHK-Cu occupies an unusual position: a mechanism that is chemically well grounded, an in vitro effect that has been replicated, a human evidence base confined almost entirely to topical cosmetic endpoints, and a set of headline claims that outrun all three. The useful discipline is to ask of any statement about this compound which of those tiers it belongs to. Copper binding is chemistry. Collagen stimulation in fibroblasts is cell culture. Improved skin appearance is a small topical trial. Systemic regenerative effects in humans are, at present, not evidence of any tier.